Wall Street analysts predict that Verastem Inc (NASDAQ:VSTM) will announce earnings per share (EPS) of ($0.40) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Verastem’s earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.34). Verastem reported earnings of ($0.43) per share during the same quarter last year, which suggests a positive year over year growth rate of 7%. The business is scheduled to announce its next quarterly earnings report on Tuesday, March 12th.
On average, analysts expect that Verastem will report full year earnings of ($1.40) per share for the current year, with EPS estimates ranging from ($1.52) to ($1.34). For the next financial year, analysts expect that the firm will post earnings of ($1.63) per share, with EPS estimates ranging from ($2.26) to ($0.85). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Verastem.
Verastem (NASDAQ:VSTM) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14. The company had revenue of $15.51 million during the quarter.
Several research firms have recently issued reports on VSTM. BidaskClub raised Verastem from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research lowered Verastem from a “buy” rating to a “hold” rating in a research report on Saturday, January 5th. ValuEngine lowered Verastem from a “buy” rating to a “hold” rating in a research report on Monday, December 17th. Roth Capital set a $14.00 price target on Verastem and gave the stock a “buy” rating in a research report on Friday, November 9th. Finally, HC Wainwright set a $15.00 price target on Verastem and gave the stock a “buy” rating in a research report on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $14.78.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in shares of Verastem by 2,520.2% in the 2nd quarter. FMR LLC now owns 4,058,097 shares of the biopharmaceutical company’s stock worth $27,920,000 after acquiring an additional 3,903,218 shares during the period. BlackRock Inc. raised its position in Verastem by 240.6% in the second quarter. BlackRock Inc. now owns 3,542,912 shares of the biopharmaceutical company’s stock valued at $24,376,000 after purchasing an additional 2,502,853 shares during the period. Man Group plc acquired a new stake in shares of Verastem during the third quarter valued at about $5,419,000. Vanguard Group Inc grew its stake in Verastem by 20.5% in the third quarter. Vanguard Group Inc now owns 3,130,491 shares of the biopharmaceutical company’s stock worth $22,696,000 after purchasing an additional 532,484 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Verastem by 20.5% in the third quarter. Vanguard Group Inc. now owns 3,130,491 shares of the biopharmaceutical company’s stock worth $22,696,000 after purchasing an additional 532,484 shares in the last quarter. Institutional investors own 48.83% of the company’s stock.
VSTM opened at $3.72 on Friday. The company has a quick ratio of 2.97, a current ratio of 2.97 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $301.81 million, a PE ratio of -2.11 and a beta of 3.21. Verastem has a 1 year low of $2.77 and a 1 year high of $10.35.
Verastem Company Profile
Verastem, Inc, operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Read More: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.